Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
13.44
-0.16 (-1.18%)
Mar 9, 2026, 3:26 PM EDT - Market open
Arvinas Employees
Arvinas had 246 employees as of December 31, 2025. The number of employees decreased by 184 or -42.79% compared to the previous year.
Employees
246
Change (1Y)
-184
Growth (1Y)
-42.79%
Revenue / Employee
$1,067,480
Profits / Employee
-$328,455
Market Cap
859.64M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,300 |
| Phathom Pharmaceuticals | 371 |
| Xencor | 250 |
| uniQure | 209 |
| Sana Biotechnology | 194 |
| ARS Pharmaceuticals | 167 |
| Janux Therapeutics | 109 |
| Arbutus Biopharma | 44 |
ARVN News
- 12 days ago - Arvinas, Inc. (ARVN) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 14 days ago - Arvinas to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 20 days ago - Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - GlobeNewsWire
- 25 days ago - Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director - GlobeNewsWire
- 3 months ago - Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition - GlobeNewsWire
- 3 months ago - Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 3 months ago - Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS) - GlobeNewsWire